Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($1.45), $1.15 worse than the analyst estimate of ($0.30).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Veeco Instruments (VECO) Misses Q3 EPS by 9c; Offers Guidance
- Progyny (PGNY) Tops Q3 EPS by 21c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
